Save the Date: The 4th Annual Summit Returns October 18, 2027
View Photo Gallery
Join Us Bubble

Connecting Investors and Business Leaders to Accelerate Cancer Innovation

Join us for an exclusive gathering of senior-level investors, corporate executives, entrepreneurs, and business leaders at the Third Annual Oncology Venture, Innovation & Partnering Summit, October 19-20, 2026, in Cambridge, MA. Connect with future investors and partners at intimate networking sessions; gain strategic insights on funding activities, exits, business development, and innovation strategies in cancer therapeutics and diagnostics from industry-led panels; and hear candid perspectives and business recommendations from oncology thought leaders during dynamic fireside chats. The Oncology Venture, Innovation & Partnering Summit is positioned as the premier meeting place for key oncology stakeholders to foster meaningful connections, acquire valuable strategic insights, and drive innovation and collaboration.

EVENT FEATURES:

  • Network with investors, CEOs, and pharma leaders at exclusive receptions and networking events
  • Gather actionable insights from oncology business leaders during engaging panel discussions
  • Strategize for commercial success and learn from oncology executives at fireside chats
  • Brainstorm most timely topics and meet future partners and investors at targeted roundtables
  • Join the annual meeting and accelerate cancer innovation!
VIP Demographics
AGENDA
SPEAKERS
REGISTER
BROCHURE

2026 Co-Chairs

Luba Greenwood
Rachel Humphrey, MD
Michal Preminger, PhD, MBA

2026 Summit Speakers:

Carla Bauer, PhD

Carla Bauer, PhD

Director, Search & Evaluation, Business Development & Licensing
Merck

Jens Bitsch-Norhave, PhD

Jens Bitsch-Norhave, PhD

Corporate Vice President & Global Head, Corporate Development
Hengrui Pharma

Christine Brennan, PhD

Christine Brennan, PhD

Partner, JJDC
Johnson & Johnson

Polly Brown

Polly Brown

Vice President, Head of Business Development, Oncology R&D
AstraZeneca

Ildiko Csiki, MD, PhD

Ildiko Csiki, MD, PhD

Head of External Innovation, Oncology
Pfizer

Stephen Curtis, PhD

Stephen Curtis, PhD

Senior Director, New Ventures, BrightEdge
American Cancer Society

Ann DeWitt, PhD

Ann DeWitt, PhD

General Partner
Engine Ventures

Anna French, DPhil

Anna French, DPhil

Managing Partner
Qiming Venture Partners

Brian Goodman, PhD

Brian Goodman, PhD

Managing Director
Vida Ventures

David Greenwald, PhD

David Greenwald, PhD

Managing Director
Deerfield Management

Luba Greenwood, JD

Luba Greenwood, JD

CEO
Mwyngil Therapeutics

Jason P. Hafler

Jason P. Hafler

Managing Director
Sanofi Ventures

Helen Ho, PhD

Helen Ho, PhD

Chief Business & Strategy Officer
Parabilis Medicines

Kat Kayser-Bricker, PhD

Kat Kayser-Bricker, PhD

CSO
Halda Therapeutics

Philina Lee, PhD

Philina Lee, PhD

CEO
AdvanCell

James Li, MD

James Li, MD

Venture Partner
Frazier Life Sciences

Jay Mei, MD, PhD

Jay Mei, MD, PhD

Founder & CEO
Antengene

Irena Melnikova, PhD

Irena Melnikova, PhD

Partner
Pfizer Ventures

Michael Partsch

Michael Partsch

Chief Venture Officer
Wisconsin Alumni Research Foundation

Michal Preminger, PhD, MBA

Michal Preminger, PhD, MBA

CEO
BioMed X Venture Labs; Former Regional Head, J&J Innovation

Jason Rhodes

Jason Rhodes

Partner
Atlas Venture

Matthew Roden, PhD

Matthew Roden, PhD

President & CEO
Aktis Oncology; Entrepreneur Partner, MPM BioImpact

Vishal Sahni, PhD

Vishal Sahni, PhD

Investment Director
Merck Global Health Innovation Fund

Uciane Scarlett, PhD

Uciane Scarlett, PhD

Former Principal
MPM BioImpact

Nandita Shangari, PhD

Nandita Shangari, PhD

Managing Director, Venture
RA Capital Management

Peter Strack, PhD

Peter Strack, PhD

Vice President, Integrative Sciences
Bristol Myers Squibb

Steven Weinstein

Steven Weinstein

CEO
Gradalis

John Wu, PhD

John Wu, PhD

Managing Director & Partner
Boston Consulting Group

View All Speakers

2026 Agenda Topics Include

  • Investing Opportunities and Outlook for Oncology Innovation in 2026
  • Big Pharma Perspective on Oncology R&D: Investment Strategies, Partnering Models, and Exit Pathways
  • Navigating China’s Rise: Partnering, Investment, and Strategic Challenges & Opportunities for US Biopharma
  • CEO Chat: Oncology CEO Perspectives on Leading through Uncertainty
  • Opportunities for Artificial Intelligence to Transform Oncology Drug Development and Healthcare
  • Next Frontiers in Oncology Therapeutics
  • Radiopharmaceuticals Venture, Innovation & Partnering
  • Keynote Fireside Chats with Featured Investor, CEO, and Big Pharma KOLs
  • Innovation Spotlights Covering AI, Emerging Therapeutics, and Radioligand Therapies
Cambridge VIP - Boston, The BioTech Hub

Who Should Attend

INVESTMENT FIRMS:

  • VC/PE/CVC Investors & Angels
  • Senior Investors (Managing Partners/Directors & General Partners)
  • Investors (Partners, Investors & Principals)
  • Portfolio Advisors (Venture & Operating Partners)

STARTUPS:

  • Emerging Company Leaders
  • Founders & CEOs
  • C-Suite Executives (CSOs, CIOs, CTOs, etc.)
  • Innovation & Strategy Managers (SVPs, VPs & Directors)

CORPORATIONS:

  • Pharmaceutical, Diagnostic, and Device Company Executives
  • Business Development Heads (SVPs, VPs & Directors)
  • Innovation & Strategy Managers (SVPs, VPs & Directors)
  • Venture Leaders (Managing Directors, Partners & Directors)

A Partial List of Perennial Players at the Summit:

Perennial Players Company Logo Collage


Scenes from Previous Oncology Venture, Innovation & Partnering Summits

2025 Photo Gallery
2025 Video Highlights

Key Contacts:

Julia Boguslavsky

CONFERENCE CONTENT

Julia Boguslavsky
Executive Director, Conferences
[email protected]

Brian Caine

PARTNERING & SPONSORSHIP

Brian Caine
Manager, Strategic Partnerships
[email protected]